Apart from anakinra, which is used in managing CAR T adverse events, canakinumab, the IL-1β neutralizing antibody, is being evaluated for the therapeutic effects in MDS and CML [8,9]. The gene discussed is IL1B; the disease is myelodysplastic syndrome.